Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: Results from the ESPOIR early synovitis cohort

Rheumatology (United Kingdom)

Volumn 51, Issue 9, 2012, Pages 1648-1654

  Gaujoux Viala, Cécile ^a   Paternotte, Simon ^b   Combe, Bernard ^c   Dougados, Maxime ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Early arthritis; Methotrexate

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DAS 28; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SHARP VAN DER HEIJDE SCORE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HEALTH STATUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); SEVERITY OF ILLNESS INDEX; SYNOVITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865321225     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes135     Document Type: Article

References (22)

1. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
2. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59: 762-84.
4. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
5. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372: 375-82.
6. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
7. Westhovens R, Robles M, Ximenes AC et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
8. Combe B, Benessiano J, Berenbaum F et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007;74:440-5.
9. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
10. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23: 137-45.
11. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27: 261-3.
12. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 2011;46:399-424.
13. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26: 734-53.
14. Brookhart MA, Schneeweiss S, Rothman KJ et al. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149-56.
15. Wiles NJ, Lunt M, Barrett EM et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 2001;44:1033-42.
16. Park GS, Wong WK, Oh M et al. Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. Stat Methods Med Res 2007;16:13-29.
17. Lukas C, Combe B, Ravaud P et al. Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: data from the Étude et Suivi des polyarthrites in différenciées récentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011;63: 1804-11.
18. Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 69:1580-8.
19. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68: 1086-93.
20. Nikolaisen C, Kvien TK, Mikkelsen K et al. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Scand J Rheumatol 2009;38:240-5.
21. Bukhari MA, Wiles NJ, Lunt M et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003;48: 46-53.
22. Kyburz D, Gabay C, Michel BA et al. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology 2011;50:1106-10.